scholarly journals Complete hematological and major molecular response through treatment with low‐dose Interferon alpha 2a in high‐risk polycythemia vera patient: a case report

2021 ◽  
Vol 9 (10) ◽  
Author(s):  
Christoph Driessen ◽  
Christoph Noppen ◽  
Georg Boonen ◽  
Juergen Drewe
Keyword(s):  
Case Report ◽  
High Risk ◽  
Polycythemia Vera ◽  
Interferon Alpha ◽  
Low Dose ◽  
Molecular Response ◽  
Major Molecular Response

scholarly journals Complete hematological and major molecular response through treatment with ultra-low dose Interferon alpha 2 in polycythemia vera: a case report

2021 ◽  
Author(s):  
Christoph Driessen ◽  
Christoph Noppen ◽  
Georg Boonen ◽  
Juergen Drewe
Keyword(s):  
Case Report ◽  
Polycythemia Vera ◽  
Interferon Alpha ◽  
Early Treatment ◽  
Low Dose ◽  
Interferon Α ◽  
Molecular Response ◽  
Major Molecular Response ◽  
Strong Reduction ◽  
Molecular Remission

Early treatment of polycythemia vera with ultra-low-dose interferon-α 2a is well tolerated and results in complete hematologic and major molecular remission and a strong reduction of all symptoms, especially pruritus and fatigue.

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

2008 ◽  
Vol 87 (10) ◽  
pp. 847-850 ◽  
Author(s):  
T. S. Larsen ◽  
O. W. Bjerrum ◽  
N. Pallisgaard ◽  
M. T. Andersen ◽  
M. B. Møller ◽  
...  
Keyword(s):  
Polycythemia Vera ◽  
Interferon Alpha ◽  
Molecular Response ◽  
Major Molecular Response ◽  
Interferon Alpha 2B

scholarly journals Germline Genetic Factors Influence Outcome of Interferon Alpha Therapy in Polycythemia Vera

Blood ◽  
2020 ◽  
Author(s):  
Roland Jäger ◽  
Heinz Gisslinger ◽  
Elisabeth Fuchs ◽  
Edith Bogner ◽  
Jelena D. Milosevic Feenstra ◽  
...  
Keyword(s):  
Polycythemia Vera ◽  
Interferon Alpha ◽  
Genetic Factors ◽  
Myeloproliferative Neoplasms ◽  
Association Studies ◽  
Study Cohort ◽  
Molecular Response ◽  
Genome Wide Association Studies ◽  
Association Analyses ◽  
Genome Wide

Interferon alpha (IFNα) based therapies can induce hematologic and molecular responses in polycythemia vera (PV); however, patients do not respond equally. Germline genetic factors have previously been implicated in differential drug response. We addressed the effect of common germline polymorphisms on hematologic and molecular response (HR/MR) in PV therapy within the PROUD-PV and CONTINUATION-PV studies including 122 patients with PV receiving ropeginterferon alfa-2b. Genome-wide association studies using longitudinal data on HR and MR over 36 months follow-up did not reveal any associations at genome-wide significance. Further, we performed targeted association analyses at the interferon lambda 4 (IFNL4) locus, well known for its role in hepatitis C viral clearance and recently reported to influence HR during therapy of myeloproliferative neoplasms. While we did not observe any association of IFNL4 polymorphisms with HR in our study cohort, we demonstrated a statistically significant effect of the functionally causative IFNL4 diplotype (haplotype pair including the protein-coding variants rs368234815/rs117648444) on MR (p=3.91x10-4; OR=10.80; 95%CI:[2.39-69.97]) as reflected in differential JAK2V617F mutational burden changes according to IFNL4 diplotype status. Stratification of PV patients based on IFNL4 functionality may allow for optimizing patient management during IFNα treatment.

167 Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response

2011 ◽  
Vol 35 ◽  
pp. S65
Author(s):  
C. Finelli ◽  
C. Clissa ◽  
M. Folio ◽  
A. Curti ◽  
S. Paolini ◽  
...  
Keyword(s):  
High Risk ◽  
Low Dose ◽  
Molecular Response

P14 Outcome of high risk melanoma patients treated with low dose interferon alpha 2B

1999 ◽  
Vol 9 (3) ◽  
pp. 328
Author(s):  
D. A. Vorobiof ◽  
D. E. Ostria ◽  
G. Vorobiof ◽  
M. R. Chasen
Keyword(s):  
High Risk ◽  
Interferon Alpha ◽  
Low Dose ◽  
Interferon Alpha 2B ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients

scholarly journals Efficacy and safety of Bosutinib in Patient with Chronic myeloid leukemia who was intolerant to DASTANIB,NILOTUNIB -Case report

2021 ◽  
pp. 225
Author(s):  
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Chronic Phase ◽  
Symptomatic Treatment ◽  
Molecular Response ◽  
Toxicity Profile ◽  
Efficacy And Safety ◽  
Major Molecular Response

Treatment for Chronic myeloid leukemia has been revolutionized because of availability of different tyrosine kinase inhibitors. Each TKI come with its on toxicity profile as this needs to be taken in account before starting therapy with particular agent in a patient. Most of the adverse effects related to TKI are mild and can be managed by either symptomatic treatment or either by dose reduction. But some patients can become intolerant and to switch to other TKI remains the only option. Bosutinib is currently approved for treatment of chronic phase CML in patients who are either resistant or intolerant to previous TKI. We present a case of 59 year old male patient with CML who was intolerant to Dastanib and Nilotinib but showed excellent hematological and major molecular response to bosutinib

scholarly journals COVID-19 Induced Pancytopenia in a Major Molecular Response CML patient on Dasatinib: A Case Report and Review of Literature

2021 ◽  
Author(s):  
Balraj Singh ◽  
Sarah Ayad ◽  
Parminder Kaur ◽  
Vinod Kumar ◽  
Sachin Gupta ◽  
...  
Keyword(s):  
Case Report ◽  
Severe Acute Respiratory Syndrome ◽  
Infected Patient ◽  
Molecular Response ◽  
Past Medical History ◽  
Review Of Literature ◽  
Major Molecular Response ◽  
Health Crisis ◽  
Wide Range ◽  
History Of

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has caused a global health crisis. COVID-19 can have a multifaceted presentation. A wide range of complications and outcomes can emerge based on the severity and comorbidities of the infected patient.  We report a 42-year-old male with past medical history of CML on Dasatinib (in Major Molecular Response) who was diagnosed with COVID-19 and developed pancytopenia. Our case and review of available reports add to the limited literature available regarding COVID-19 in CML.

scholarly journals Safety and efficacy of nilotinib after 10 years of interferon

2015 ◽  
Vol 6 (2S) ◽  
pp. 19-22
Author(s):  
Filippo Russo
Keyword(s):  
High Risk ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Standard Dose ◽  
Interferon Alfa ◽  
Molecular Response ◽  
Major Molecular Response ◽  
Safety And Efficacy ◽  
Optimal Response ◽  
Complete Molecular Response

Here we describe a case of a woman with chronic myeloid leukemia at high risk, according to the Sokal Index. The patient started interferon alfa-2b (IFN) at standard dose obtaining a major molecular response after about four years of treatment. After about 10 years the patient presented a toxicity from IFN and different comorbidities, so she was switched to nilotinib and achieved a complete molecular response (MR4). This case shows how nilotinib is effective and tolerable also in patients with multiple comorbidities. Keywords: Chronic myeloid leukemia; Optimal response; Nilotinib; Interferon alfa-2b

Sign in / Sign up

Export Citation Format

Share Document